Log in Subscribe

Compared with the controls, a higher faecal dry matter content was observed in the animals immunized with either FCA or QuilA

Albrektsen Humphries
· 3 min read
Compared with the controls, a higher faecal dry matter content was observed in the animals immunized with either FCA or QuilA

The change in faecal dry matter content was positively associated with the faecal antibody concentration (R2 = 0.441, p < 0.05). These results indicate that FIA and QuilA were effective at inducing high levels of antibody responses to S. bovis, and suggest that either Freund's incomplete adjuvant or QuilA may be useful for preparing a practically acceptable vaccine against lactic acidosis.group A and group C meningococcal polysaccharide vaccines.

Measurement of meningococcal antibody levels in individual serum samples by the haemagglutination technique showed that two years after vaccination the mean group A meningococcal antibody level was no higher in immunized subjects than in 140 age-matched, non-immunized controls. Over-all the mean group C meningococcal haemagglutinating antibody level was significantly higher in immunized subjects than it was in controls but this difference was not found in those under the age of 15 years at the time of vaccination. However, when pooled serum samples from the same subjects were tested for meningococcal antibodies by radioimmunoassay, immunized subjects were found to have significantly higher mean levels of both group A and group C meningococcal antibodies than the controls. The possible reasons for this discrepancy are considered and the significance of these findings in relation to plans for mass immunization with meningococcal vaccines in tropical Africa are discussed.Healthcare Workers after Primary Immunization with ChAdOx1-S and Booster SARS-CoV-2 ancestral strain, and Delta and Omicron (BA.1 and BA.2) variants in Vietnamese healthcare workers (HCWs) up to 15 weeks after booster vaccination.

We included 47 HCWs, including group 1 (G1, N = 21) and group 2 (G2; N = 26) without and with breakthrough Delta variant infection before booster immunization, respectively). The study participants had completed primary immunization with ChAdOx1-S and booster vaccination with BNT162b2. Neutralizing antibodies were measured using a surrogate virus neutralization assay. Of the 21 study participants in G1, neutralizing antibodies against ancestral strain, Delta variant, BA.1, and BA.2 were (almost) abolished at month 8 after the second dose, but all had detectable neutralizing antibodies to the study viruses at week 2 post booster dose. Of the 26 study participants in G2, neutralizing antibody levels to BA.

1 and BA.2 were significantly higher than those to the corresponding viruses measured at week 2 post breakthrough infection and before the booster dose. At week 15 post booster vaccination, neutralizing antibodies to BA.1 and BA.2 dropped significantly, with more profound changes observed in those without breakthrough Delta variant infection. Booster vaccination enhanced neutralizing activities against ancestral strain and Delta variant compared with those induced by primary vaccination. These responses were maintained at high levels for at least 15 weeks.

Our findings emphasize the importance of the first booster dose in producing cross-neutralizing antibodies against Omicron variant. A second booster to maintain long-term vaccine effectiveness against the currently circulating variants merits further research.ChAdOx1-nCoV-19/mRNA-1273 prime-boost vaccination".Streptococcus pyogenes: preparation of anti-T factor sera.for anti-DNA, anticardiolipin, anti-Sm, anti-Sm/RNP, anti-Ro and anti-La. Blood samples were withdrawn at the time of vaccination and 6 and 12 weeks after vaccination. The mean age at enrolment into the study was 46.

1 years. The mean disease duration was 9.1 years.  vitamin b5 deficiency  were 6.6 at vaccination, 4.9 at 6 weeks and 5.1 at week 12.

Seebio vitamin b5 deficiency  was not associated with the generation of anti-DNA. At time of vaccination a single patient had anti-Sm, four patients had anti-Sm/RNP antibodies, none of the patients had anti-La antibody and six had anti-Ro antibodies. Six weeks after vaccination four, eight, nine and three patients had autoantibodies reacting with Sm, Sm/RNP, Ro and La, respectively. Twelve weeks after vaccination none of the patients had anti-Sm, three had anti-Sm/RNP, five had anti-Ro and two had anti-La antibodies. Following vaccination six and three patients developed IgG and IgM anticardiolipin antibodies, respectively.